PharmaCyte Biotech (PMCB) Interest Expenses (2010 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Interest Expenses of $19.4 million for Q2 2026, up 27.24% year-over-year from $15.2 million in Q2 2025, and up 27.24% quarter-over-quarter from $15.2 million in Q2 2025.
PharmaCyte Biotech (PMCB) Interest Expenses (2010 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Interest Expenses for 16 consecutive years, with $19.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest Expenses rose 27.24% year-over-year to $19.4 million; the TTM figure through Apr 2026 stood at $19.4 million (up 27.24% YoY), while the FY2026 annual figure was $19.4 million, up 27.24% from the prior year.
- Interest Expenses rose to $19.4 million in Q2 2026 per PMCB's latest filing, from $15.2 million in the prior quarter.
- Across five years, Interest Expenses topped out at $19.4 million in Q2 2026 and bottomed at -$4964.0 in Q1 2023.
- Historically, Interest Expenses has averaged $7.1 million across 5 years, with a median of $4253.0 in 2022.
- Annual changes were most pronounced in 2022 — Interest Expenses soared 144.12% — and 2023, when it tumbled 216.72%.
- PharmaCyte Biotech's Interest Expenses stood at $2316.0 in 2022, then slumped by 314.34% to -$4964.0 in 2023, then surged by 306178.16% to $15.2 million in 2024, then advanced by 0.18% to $15.2 million in 2025, then grew by 27.24% to $19.4 million in 2026.
- Business Quant data shows PMCB's Interest Expenses at $19.4 million in Q2 2026, $15.2 million in Q2 2025, and $15.2 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.91 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.87 Bn | 59.68 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.18 Bn | 53.04 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.96 Bn | 36.87 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.23 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 27.79 Bn | 9.40 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.37 Bn | 26.53 Bn | - | 93.62 Mn |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 19.37 Mn |
| Apr 30, 2026 | 19.37 Mn |
| Apr 30, 2025 | 15.22 Mn |
| Apr 30, 2025 | 15.22 Mn |
| Apr 30, 2024 | 15.19 Mn |
| Apr 30, 2024 | 15.19 Mn |
| Jan 31, 2023 | -4,964.00 |
| Jan 31, 2023 | -4,964.00 |
| Oct 31, 2022 | 2,316.00 |
| Oct 31, 2022 | 2,316.00 |
| Jul 31, 2022 | 3,906.00 |
| Jul 31, 2022 | 3,906.00 |
| Jan 31, 2022 | 4,253.00 |
| Jan 31, 2022 | 4,253.00 |
| Oct 31, 2021 | 6,880.00 |
| Oct 31, 2021 | 6,880.00 |
| Jul 31, 2021 | 1,600.00 |
| Jul 31, 2021 | 1,600.00 |
| Apr 30, 2021 | 261.00 |
| Apr 30, 2021 | 261.00 |